Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 270 participants.
Also called NCT02551172
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 270 participants
- Registry
-
NCT02551172
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT02551172. Randomized; double masking; primary purpose treatment. Start 2014-10 (registry gives no type); primary completion 2016-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD
- Condition
- Hyperlipidemias
- Intervention (Drug)
- HCP1105
- Intervention (Drug)
- HGP0816
- Intervention (Drug)
- Placebo of HCP1105
- Intervention (Drug)
- Placebo of HGP0816
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct02551172- Content hash
3a21816171d8a9c378495bbdb56ef418b29a23bcbceebd0bfc6863c5e2d7415d